Skip to main content
. Author manuscript; available in PMC: 2015 Feb 1.
Published in final edited form as: Adv Drug Deliv Rev. 2013 Nov 21;0:26–41. doi: 10.1016/j.addr.2013.11.004

Figure 5.

Figure 5

Evaluation of efficacy of mitochondria-targeted liposomes. The liposomal surface was modified with a co-polymer, triphenylphosphonium-PEG-PE conjugate, for mitochondrial targeting (TPP-L). (A) Confocal microscopy of HeLa cells treated with rhodamine-labeled unmodified liposomes (PL) and TPP-L. Yellow dots in the merged picture indicate co-localization of red (liposome) and green (mitotracker) signals. (B) Evaluation of the cell-killing efficacy of paclitaxel-loaded TPP-L (TPP-L-PTX) on HeLa cells. The targeted delivery of paclitaxel to mitochondria resulted in a further decrease in cell viability. (C) The in vivo evaluation of the efficacy of TPP-L-PTX in reducing tumor volume. The arrows indicate the day of intravenous administration of liposomes at a paclitaxel dose of 1 mg/Kg. The significantly higher reduction in tumor volumes (p<0.01) indicated the higher therapeutic efficacy of mitochondrial-targeted PTX liposomes.